Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

NCT01020539 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Juvenile Myelomonocytic Leukemia

Interventions

DRUG: Fludarabine
DRUG: Busulfan
DRUG: GVHD Prophylaxis
DRUG: Gemtuzumab Ozogamicin
DRUG: Anti-Thymocyte Globulin
DRUG: Isotretinoin

Sponsor

Columbia University